Skip to content
AnalystLens

Idex Quarterly Report for Q1 Ended Mar 31, 2024

Filing Date
Filed April 24, 2024
Period End
March 31, 2024
Security
IEX
One revenue dollarkept$0.15
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation reported first-quarter 2024 net sales of $800.5 milliona, down from $845.4 million in the prior-year quarter, with organic net sales declining 6% as lower volumes in the Health & Science Technologies segment offset price capture across all segments.

Net income attributable to IDEX was $121.4 millionb, or $1.60 diluted EPS, compared with $139.8 million and $1.84 a year earlier. Gross margin fell to 44.6% from 45.2%, and operating income declined to $161.2 million from $192.3 million, with the filing citing lower volume leverage and higher employee-related costs. Adjusted diluted EPS was $1.88 versus $2.09, per the company's non-GAAP reconciliation.

Cash generation remained solid. Cash flows from operating activities rose to $156.6 millionc from $147.9 million, driven mainly by lower cash payments for variable compensation, and free cash flow was $136.6 million versus $121.3 million. Cash and cash equivalents increased to $616.3 million at March 31, 2024, while total borrowings were $1,330.9 million and the Revolving Facility had $717.8 million of net availability.

The company made no share repurchases during the quarter, leaving $539.7 milliond of authorization remaining, and paid $48.5 million in dividends. The Health & Science Technologies segment was the main source of weakness, with net sales down 12% and Adjusted EBITDA down 19%, attributed to inventory recalibration and market slowness in analytical instrumentation, life sciences and semiconductor markets.

Fluid & Metering Technologies sales declined 3%, while Fire & Safety/Diversified Products grew 2%. The company stated it expects no material impact from the OECD Pillar Two global minimum tax rules.

Key Highlights

  1. Net sales of $800.5 million, down 5% from $845.4 million; organic net sales down 6%
  2. Diluted EPS attributable to IDEX of $1.60 vs. $1.84; adjusted diluted EPS of $1.88 vs. $2.09
  3. Adjusted EBITDA of $208.3 million vs. $229.8 million, with Adjusted EBITDA margin of 26.0% vs. 27.2%
  4. Health & Science Technologies net sales down 12% and Adjusted EBITDA down 19%, driven by lower volumes and inventory recalibration
  5. Operating cash flow of $156.6 million (up 6%) and free cash flow of $136.6 million (up 13%)
  6. Acquisitions of Iridian ($109.8 million) in May 2023 and STC ($200.4 million) in December 2023 contributed to net sales growth of 1%
  7. No share repurchases in the quarter; $539.7 million of authorization remaining; $48.5 million in dividends paid

Follow one dollar

Of each $1.00 of revenue in Q1 FY2024, Idex kept $0.15.

  1. Revenue$800.5M100.0%
  2. Cost of revenue−$443.1M55.4%
  3. Gross profit$357.4M44.6%
  4. Operating costs−$196.2M24.5%
  5. Operating income$161.2M20.1%
  6. Interest, other & tax−$39.8M5.0%
  7. Net income$121.4M15.2%
Computed from 10-QQ1 FY2024filed April 24, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$800.50M$845.40M−5.3%
Cost of Revenue$443.10M$462.90M−4.3%
Gross Profit$357.40M$382.50M−6.6%
SG&A Expenses$195.10M$189.70M+2.8%
Operating Income$161.20M$192.30M−16.2%
Interest Expense$9.40M$13.10M−28.2%
Net Income$121.40M$139.80M−13.2%
EPS (Basic)$1.60$1.85−13.5%
EPS (Diluted)$1.60$1.84−13.0%
Shares Outstanding (Basic)75.70M75.60M+0.1%
Shares Outstanding (Diluted)75.90M75.90M0.0%

Frequently Asked Questions

  1. Why did IDEX's earnings decline in the first quarter of 2024?

    Net income attributable to IDEX fell 13% to $121.4 million, driven by lower operating income of $161.2 million versus $192.3 million. The filing attributes the gross profit decline to lower volume leverage and higher employee-related costs, partially offset by strong price/cost and favorable operational productivity. Restructuring expenses also rose to $1.1 million from $0.5 million due to higher severance costs.

  2. Which business segment was most affected by the weaker results?

    The Health & Science Technologies segment was most affected, with net sales declining 12% to $310.1 million and Adjusted EBITDA falling 19% to $81.4 million. The filing cites lower volumes in analytical instrumentation, life sciences and semiconductor markets, largely driven by inventory recalibration and market slowness carried over from 2023.

  3. How strong is IDEX's liquidity and balance sheet?

    Cash and cash equivalents rose to $616.3 million at March 31, 2024, and the company had a current ratio of 3.4 to 1 and working capital of $1,093.9 million. Total borrowings were $1,330.9 million, and the company reported it was in compliance with its financial covenants, with an interest coverage ratio of 18.48 to 1 and a leverage ratio of 1.49 to 1.

  4. Did IDEX change its share repurchase or dividend activity?

    IDEX made no share repurchases during the first quarter of 2024 or 2023. Dividend payments to common shareholders totaled $48.5 million, compared with $45.5 million a year earlier. The company had $539.7 million of share repurchase authorization remaining as of March 31, 2024.

  5. What is the company's exposure to tax and acquisition-related items?

    The effective tax rate decreased to 21.5% from 22.2%, primarily due to a discrete benefit from finalizing tax impacts of a previously recorded legal entity restructuring. The company stated it does not expect a material impact from the OECD Pillar Two global minimum tax rules. Acquisition-related costs were $1.3 million, and a $2.5 million fair value inventory step-up charge related to the STC acquisition was recorded in cost of sales.